Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.41 |
| ▸ | NLN | Q9BYT8 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | CDK7 | P50613 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16355384 | 0.85 | HDAC1 (0.41) | HDAC1NLNOPRD1 | |
| SCHEMBL14948297 | 0.78 | LIPG (0.44) | HDAC1NLN | |
| SCHEMBL15585984 | 0.76 | CYP2A6 (0.47) | CYP1A2CYP2A6ABL1RETKDR | |
| SCHEMBL15443594 | 0.75 | NLN (0.48) | HDAC1NLN | |
| SCHEMBL15586280 | 0.74 | CYP1A2 (0.39) | NLNCYP1A2CYP2A6NPY5R | |
| SCHEMBL15443396 | 0.74 | NLN (0.47) | HDAC1NLN | |
| SCHEMBL18870202 | 0.74 | CYP2A6 (0.42) | CYP1A2CYP2A6ABL1RETKDR | |
| SCHEMBL21896673 | 0.72 | GSK3B (0.44) | HDAC1NLNCYP2A6 | |
| SCHEMBL14300085 | 0.72 | NPC1 (0.34) | HDAC1NLNOPRD1 | |
| SCHEMBL12107456 | 0.72 | AAK1 (0.42) | HDAC1NLNOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382261-B2 | Substituted quinazolinones as HCV inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-07-05 | — | — | US | disclosed |
| US-20140378485-A1 | QUINAZOLINONE DERIVATIVES AS HCV INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2014-12-25 | — | — | US | disclosed |
| US-8815849-B2 | Hetero-bicyclic derivatives as HCV inhibitors | JANSSEN R&D IRELAND (IE) | 2014-08-26 | — | — | US | disclosed |
| US-20130123244-A1 | Hetero-Bicyclic Derivatives as HCV Inhibitors | JANSSEN R&D IRELAND (IL) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378485-A1 | QUINAZOLINONE DERIVATIVES AS HCV INHIBITORS | EIF2AK2, NQO2, IRF3 | HDAC1 1199/4885NLN 4200/4885CYP1A2 246/4885 |
| US-20130123244-A1 | Hetero-Bicyclic Derivatives as HCV Inhibitors | HAVCR2, ZC3HAV1, SUB1 | HDAC1 222/4885NLN 4702/4885CYP1A2 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.